Recent Updates
Recently added Catalysts
NRXP Positive Sentiment

NRx Pharmaceuticals Unveils potential Treatment for Suicidal Thoughts and Depression

Wednesday, November 29, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NRx Pharmaceuticals is making significant strides in treating suicidal thoughts and depression. Dr. Jonathan Javitt announced that the company is close to meeting its clinical trial enrollment goals for NRX-101. Additionally, NRX is expanding its clinical initiatives to include treatments for chronic pain and urinary tract infections.
Price reaction · baseline $3.356 (2023-11-29T17:30:00.000Z) · hit during market hours · 1 other NRXP headline(s) in the window, move may be shared
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • NRX Pharmaceuticals is nearing clinical trial enrollment goals for NRX-101.
  • New clinical initiatives are being launched for chronic pain and urinary tract infections.
  • The company is focusing on innovative treatments for suicidal depression.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression

Full Press Release Details

Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.
Javitt told Proactive in a video presentation that NRX is approaching the clinical trial enrollment goals for its partnered product NRX-101. In addition, NRX is opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression.
Read More – https://www.proactiveinvestors.com/companies/news/1033413/nrx-pharmaceuticals-founder-unveils-potential-treatment-for-suicidal-thoughts-and-depression-1033413.html
Also found in the following articles:
• Wall Street Journal
• Nasdaq.com
• Benzinga
• Barron’s

Frequently Asked Questions

What is NRX-101?

NRX-101 is a partnered product by NRx Pharmaceuticals aimed at treating suicidal thoughts and depression.

What new initiatives is NRx Pharmaceuticals launching?

NRx Pharmaceuticals is launching new clinical initiatives for chronic pain and urinary tract infections.

Who discussed the developments at NRx Pharmaceuticals?

Dr. Jonathan Javitt discussed the groundbreaking developments in a video presentation.

What are the goals for NRX-101?

The company is approaching its clinical trial enrollment goals for NRX-101.

ShareAdd on Google
Tags: NRXP Viatris Investor Conferences Healthcare NRX Pharmaceuticals depression treatment suicidal thoughts clinical trials chronic pain
Last updated: Nov 29, 2023

Biotech snapshot

Cash runway
$27M liquidity · $2M/mo burn
~12 mo
Low dilution risk
Lead asset
NRX-101Phase 2
Bipolar Depression →

Catalyst track record

+167%
best trade around NRXP's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for NRXP.

See every catalyst's timing & PoA →